Karyopharm Therapeutics

Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company focused on the discovery and development of drugs directed against nuclear transport targets for the treatment of cancer and other diseases. The Company is developing small molecule Selective Inhibitor of Nuclear Export (SINE), compounds that inhibits the nuclear export protein XPO1. Karyopharm is seeking the regulatory approval and commercialization of its lead drug candidate, selinexor (KPT-330), as a single orally administered agent in cancer indications with unmet clinical need, initially for hematologic malignancies. It is also advancing the clinical development of selinexor in multiple solid tumor indications. The Company has initiated three registration-directed trials in hematological cancers with selinexor and anticipates initiating a fourth registration-directed trial.

Company Growth (employees)
Type
Public
HQ
Newton, US
Founded
2008
Size (employees)
108 (est)+3%
Karyopharm Therapeutics was founded in 2008 and is headquartered in Newton, US

Key People at Karyopharm Therapeutics

Michael Kauffman

Michael Kauffman

Chief Executive Officer &Board of Directors
John McCartney

John McCartney

Senior Director, Product Leadership
Brian Austad

Brian Austad

Vice President, Head of Pharmaceutical Sciences
Dilara McCauley

Dilara McCauley

Vice President, Product Leadership

Karyopharm Therapeutics Office Locations

Karyopharm Therapeutics has offices in Newton and München
Newton, US (HQ)
85 Wells Ave
München, DE
9 Franziska-Bilek-Weg

Karyopharm Therapeutics Data and Metrics

Karyopharm Therapeutics Financial Metrics

Karyopharm Therapeutics's revenue was reported to be $250 k in FY, 2015
USD

Net income (Q1, 2017)

(29.9 m)

EBIT (Q1, 2017)

(30.3 m)

Market capitalization (17-Aug-2017)

373.5 m

Cash (31-Mar-2017)

25.6 m
Karyopharm Therapeutics's current market capitalization is $373.5 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

387 k229 k250 k

Revenue growth, %

(41%)9%

R&D expense

28.5 m60.1 m97.7 m86.9 m

General and administrative expense

5.9 m15.9 m21.6 m23.9 m

Operating expense total

34.3 m76.1 m119.3 m110.9 m

EBIT

(34 m)(75.8 m)(119.1 m)(110.7 m)

EBIT margin, %

(8773%)(33121%)(47630%)

Interest expense

1 k(1 k)

Interest income

3 k97 k897 k1.3 m

Pre tax profit

(109.4 m)

Income tax expense

(139 k)

Net Income

(33.9 m)(75.8 m)(118.2 m)(109.6 m)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

R&D expense

13.2 m16 m20.8 m27 m25.9 m21.8 m24.6 m19.9 m24.1 m

General and administrative expense

3.3 m3.8 m5.4 m6.2 m4.8 m5.6 m6 m5.9 m6.3 m

Operating expense total

16.5 m19.8 m26.2 m33.2 m30.7 m27.3 m30.5 m25.8 m30.3 m

EBIT

(16.4 m)(19.7 m)(26.2 m)(33 m)(30.6 m)(27.3 m)(30.5 m)(25.7 m)(30.3 m)

Interest income

17 k20 k141 k267 k239 k286 k329 k311 k400 k

Pre tax profit

(29.9 m)

Income tax expense

(23 k)

Net Income

(16.4 m)(19.7 m)(26.1 m)(32.7 m)(30.4 m)(27.1 m)(30.2 m)(25.4 m)(29.9 m)
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

156 m150.6 m58.4 m49.7 m

Inventories

2 m2 m2 m2.1 m

Current Assets

158 m207.8 m177.6 m131.6 m

PP&E

240 k2.8 m3.5 m2.8 m

Total Assets

158.2 m220.3 m215.4 m180.4 m

Accounts Payable

1.7 m6.3 m3.8 m4.8 m

Current Liabilities

3.3 m12.3 m15.1 m16.5 m

Total Liabilities

18.1 m

Additional Paid-in Capital

217.5 m345.2 m455.2 m528.6 m

Retained Earnings

(138.3 m)(256.5 m)(366.1 m)

Total Equity

154.9 m206.8 m198.4 m162.2 m

Financial Leverage

1 x1.1 x1.1 x1.1 x
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

132.3 m227.1 m51.5 m24.2 m43.5 m42.2 m37.7 m43.9 m25.6 m

Current Assets

135.3 m231.3 m249.3 m225.3 m198.3 m138.1 m124.2 m130.3 m112.2 m

PP&E

604 k2.7 m3.3 m3.2 m3.7 m3.3 m3.2 m3 m2.7 m

Total Assets

137.7 m235.2 m292 m263.3 m237 m192.1 m170.9 m183.6 m155.4 m

Accounts Payable

3.5 m2.1 m7 m4.5 m4.6 m4.1 m4.1 m2.2 m4.2 m

Current Liabilities

5.6 m6.2 m14.7 m14.1 m14.4 m13.2 m15.5 m15 m15.5 m

Additional Paid-in Capital

224.4 m340.2 m439.9 m444.6 m448.1 m460.5 m467.2 m506.1 m534.8 m

Retained Earnings

(92.7 m)(112.4 m)(164.4 m)(197.1 m)(227.5 m)(283.6 m)(313.7 m)(339.2 m)(396.3 m)

Total Equity

131.7 m227.8 m275.5 m247.3 m220.6 m177 m153.6 m166.9 m138.4 m

Financial Leverage

1 x1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.1 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(33.9 m)(75.8 m)(118.2 m)(109.6 m)

Depreciation and Amortization

144 k323 k634 k717 k

Inventories

(1.4 m)(45 k)(55 k)(120 k)

Accounts Payable

664 k4.5 m(2.4 m)945 k

Cash From Operating Activities

(30.3 m)(51.4 m)(94 m)(84.4 m)

Purchases of PP&E

(57 k)(2.8 m)(1.4 m)(70 k)

Cash From Investing Activities

(57 k)(67 m)(90.8 m)24.6 m

Cash From Financing Activities

185.9 m113.1 m92.7 m51.2 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(16.4 m)(19.7 m)(26.1 m)(32.7 m)(30.4 m)(27.1 m)(30.2 m)(25.4 m)(29.9 m)

Accounts Payable

3.5 m2.1 m7 m4.5 m4.6 m4.1 m4.1 m2.2 m4.2 m
Y, 2017

Financial Leverage

1.1 x

Karyopharm Therapeutics Operating Metrics

FY, 2015

Patents Issued

10

Karyopharm Therapeutics Market Value History

Traffic Overview of Karyopharm Therapeutics

Karyopharm Therapeutics Online and Social Media Presence

Karyopharm Therapeutics News and Updates

BRIEF-Karyopharm completes enrollment in ongoing storm study; results expected mid-2016

* To report top-line data from phase 1b clinical trial of selinexor in combination with some agents over next 18 months Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

Karyopharm Therapeutics Company Life and Culture

You may also be interested in